1. Treatment outcomes of PCR-positive acute retinal necrosis.
- Author
-
Sidiqi AM, Bhalla M, Khan HM, Chan F, Lowe C, and Navajas EV
- Subjects
- Humans, Valacyclovir, Retrospective Studies, Herpesvirus 3, Human genetics, Treatment Outcome, Polymerase Chain Reaction, Retinal Necrosis Syndrome, Acute diagnosis, Retinal Necrosis Syndrome, Acute etiology, Retinal Detachment, Cytomegalovirus Infections complications
- Abstract
Background: Acute retinal necrosis (ARN) is a progressive necrotizing retinitis caused by viral infection. Optimal management strategies have not been established for this detrimental disease. Previous literature published suggests that Varicella-zoster virus (VZV) and Herpes simplex virus-1 (HSV1) are the most common promoters of acute retinal necrosis (ARN)., Aims: The purpose of our study was to investigate the viral distribution, demographic, and treatment outcomes of ARN., Methods: A retrospective chart review evaluated data from PCR-positive ARN patients diagnosed between 2009 and 2018., Results: Analysis of fourteen eyes from 12 patients found CMV and VZV as the commonest causes of ARN. Patients on 1 g of valacyclovir three times a day (V1T) had worse vision between first and final visits (mean difference of 1.25 ± 0.65, n = 2) compared with patients treated with 2 g of valacyclovir three times a day (V2T), or 900 mg twice a day of valganciclovir (V9B) (mean difference of - 0.067 ± 0.13, n = 6, and 0.067 ± 0.067, n = 6, respectively). Both V1T patients developed retinal detachments (RD). Both CMV patients treated with intravitreal triamcinolone developed ARN, elevated IOP, and one developed multiple RD., Conclusions: Our review found increased incidence of CMV-positive ARN. Patients with zone 1 disease had worse initial visual acuity. Moreover, patients had more favorable outcomes with V2T and V9B compared to V1T. CMV-positive patients clinically worsened after intravitreal steroid injections, further underscoring the value of a PCR diagnosis to tailor the patients' treatment plan accordingly., (© 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.)
- Published
- 2024
- Full Text
- View/download PDF